DNMT3A and acute myeloid leukemia: Given that the random forest-based risk score is independent of known prognosticators, such as ELN classification and DNMT3A, FLT3, NP1, IDH1, and CEBPA mutations, the risk score may be useful for the risk stratification of AML patients who have favorable or indeterminate cytogenetics risk or no mutations in key driver genes.